MWNA
PGNX

Marshall Wace North America’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Marshall Wace North America’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-162,869
Closed -$1.14M – 1620
2017
Q2 		$1.14M Buy
+162,869
New +$1.2M 0.01% 906

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Marshall Wace North America's PGNX Position: Q3 2017 in Review

Marshall Wace North America sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 162,869 shares — an estimated $1.14M sold.

Marshall Wace North America first reported a position in PGNX in Q2 2017 and held it in 1 quarter. The position peaked at $1.14M in Q2 2017. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • Marshall Wace North America reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Marshall Wace North America sold 162,869 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $1.14M.
  • Marshall Wace North America first reported a position in Progenics Pharmaceuticals Inc in Q2 2017 and held it in 1 quarter.
  • Marshall Wace North America's Progenics Pharmaceuticals Inc position peaked at $1.14M in Q2 2017.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on Marshall Wace North America's 13F filing for Q3 2017, filed 13 Nov 2017.